Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Sarah Joanne WilliamsPrincipal Accounting Officer | AN2 TherapeuticsANTX | Open-market sale | 05/29 | 06/02 | 265 sh | $4.43 | $1,173.95 | −0.4% |
Sarah Joanne WilliamsPrincipal Accounting Officer | AN2 TherapeuticsANTX | Open-market sale | 03/03 | 03/05 | 327 sh | $1.06 | $346.62 | −0.5% |
AN2 TherapeuticsANTX | Open-market sale | 01/05–01/06 | 01/07 | 9,251 sh2 trades | $1.01avg. | $9,310.56 | −10.9% | |
AN2 TherapeuticsANTX | Open-market sale | 01/05–01/06 | 01/07 | 8,807 sh2 trades | $1.01avg. | $8,862.12 | −10.5% | |
AN2 TherapeuticsANTX | Open-market sale | 01/05–01/06 | 01/07 | 24,854 sh2 trades | $1.00avg. | $24,923.31 | −14.0% | |
AN2 TherapeuticsANTX | Open-market sale | 01/05–01/06 | 01/07 | 6,462 sh2 trades | $1.00avg. | $6,490.58 | −9.9% | |
Joshua M. EizenSEE REMARKS | AN2 TherapeuticsANTX | Open-market sale | 25/11/04 | 25/11/06 | 2,819 sh | $1.14 | $3,213.66 | −1.6% |
Stephen David PriorChief Strategy Officer | AN2 TherapeuticsANTX | Open-market sale | 25/11/04 | 25/11/06 | 765 sh | $1.14 | $872.1 | −1.2% |
Braden Michael Leonard10% Owner | AN2 TherapeuticsANTX | Open-market sale | 25/05/28 | 25/06/16 | 200,000 sh | $1.09 | $218,000 | −6.2% |
Eric EasomCEO | AN2 TherapeuticsANTX | Open-market buy | 25/06/02 | 25/06/03 | 10,000 sh | $1.07 | $10,700 | +4.1% |
AN2 TherapeuticsANTX | Open-market sale | 25/05/28–25/05/30 | 25/05/30 | 2,532,000 sh4 trades | $1.13avg. | $2,872,460 | −44.0% | |
Margaret M. FitzPatrickDirector | AN2 TherapeuticsANTX | Open-market buy | 25/05/28 | 25/05/29 | 8,610 sh | $1.18 | $10,159.8 | No record |
Sanjay ChandaChief Development Officer | AN2 TherapeuticsANTX | Open-market sale | 25/01/03 | 25/01/07 | 2,957 sh | $1.34 | $3,962.38 | −9.0% |
Lucy DayCFO | AN2 TherapeuticsANTX | Open-market sale | 25/01/03 | 25/01/07 | 2,957 sh | $1.34 | $3,962.38 | −8.3% |
Joshua M. EizenSEE REMARKS | AN2 TherapeuticsANTX | Open-market sale | 25/01/03 | 25/01/07 | 9,663 sh | $1.34 | $12,948.42 | −7.6% |
Stephen David PriorChief Strategy Officer | AN2 TherapeuticsANTX | Open-market sale | 25/01/03 | 25/01/07 | 2,029 sh | $1.34 | $2,718.86 | −5.7% |
AN2 TherapeuticsANTX | Open-market buy | 24/12/06–24/12/10 | 24/12/10 | 60,000 sh6 trades | $1.45avg. | $86,784.56 | +10.1% | |
Joseph S. ZakrzewskiDirector | AN2 TherapeuticsANTX | Open-market buy | 24/11/27 | 24/11/27 | 2,000 sh | $1.40 | $2,800 | +1.6% |
AN2 TherapeuticsANTX | Open-market buy | 24/11/26–24/11/27 | 24/11/27 | 75,000 sh4 trades | $1.41avg. | $105,750 | +13.7% | |
AN2 TherapeuticsANTX | Open-market buy | 24/11/19–24/11/20 | 24/11/21 | 200,000 sh4 trades | $1.07avg. | $213,000 | +63.5% |